All In Biotech

Drug Trial Radar · NCT07501832

Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Moderate to Severe Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Apr 29, 2026

Primary completion

Sep 28, 2028

Study completion Sep 28, 2028

Sponsor

Lead sponsor
Gan & Lee Pharmaceuticals.Industry
Sponsor type
Industry
First posted
Mar 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of GZR18 injection in Chinese adult obese patients with moderate-to-severe obstructive sleep apnea (OSA) who are currently using positive airway pressure (PAP) therapy. This study will assess the impact of GZR18 on OSA-related symptoms, respiratory parameters, and quality of life compared to placebo.

Conditions

  • Obstructive Sleep Apnea (OSA)

Interventions

  • GZR18 injectionDrug

    subcutaneous administration

  • PlaceboDrug

    subcutaneous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Apnea-Hypopnea Index (AHI) after 52 weeks of treatmentTime frame: 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gan & Lee Pharmaceuticals

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.